Advanced Search
LIAO Yiran, ZHANG Qiuning, SHAO Lihua, LIU Ruifeng, LUO Hongtao, WANG Lina, FENG Shuangwu, YANG Kehu, WANG Xiaohu. Safety and Efficacy of Carbon Ion and Proton Therapies for Pancreatic Cancer: A Systematic Review and Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2020, 47(7): 504-510. DOI: 10.3971/j.issn.1000-8578.2020.19.1482
Citation: LIAO Yiran, ZHANG Qiuning, SHAO Lihua, LIU Ruifeng, LUO Hongtao, WANG Lina, FENG Shuangwu, YANG Kehu, WANG Xiaohu. Safety and Efficacy of Carbon Ion and Proton Therapies for Pancreatic Cancer: A Systematic Review and Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2020, 47(7): 504-510. DOI: 10.3971/j.issn.1000-8578.2020.19.1482

Safety and Efficacy of Carbon Ion and Proton Therapies for Pancreatic Cancer: A Systematic Review and Meta-analysis

More Information
  • Corresponding author:

    WANG Xiaohu, E-mail: xhwang@impcas.as.cn

  • Received Date: November 27, 2019
  • Revised Date: March 30, 2020
  • Available Online: January 12, 2024
  • Objective 

    To evaluate the safety and efficacy of carbon ion and proton therapies for pancreatic cancer (PaC).

    Methods 

    The databases were electronically searched to collect the studies about the carbon ion and proton therapies for PaC from inception to June 2019. Two reviewers independently screened literature and extracted data. A Meta-analysis was performed by STATA 12.0 and MetaAnalyst Beta 3.13 software.

    Results 

    A total of 8 studies involving 459 PaC patients were included. The incidence of grade 2, 3 and 5 gastrointestinal (GI) ulcer toxicities in PaC patients treated with carbon ion and proton therapies were 7%, 2% and 0; the incidence of grade 2, 3 and 4 anorexia toxicities were 6%, 3.2% and 0; the 1- and 2-year OS rates were 77% and 45%; the 2-year local control (LC), 1-year freedom from local progression (FFLP) and 1-year local recurrence(LR) rates were 81%, 88% and 15%. The incidence of grade 2, 3, 2-3 GI ulcer toxicities in carbon ion and proton therapies for PaC were 6.8%, 1.5%, 9.2% and 3.5%, 8.3%, 6.1% (P < 0.05); and the 1- and 2-year OS were 77.1%, 44.4% and 77.6%, 49.7% (P > 0.05).

    Conclusion 

    Carbon ion and proton therapies for PaC are safe and effective; and the security and effectiveness of the two methods are similar.

  • [1]
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
    [2]
    Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
    [3]
    Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States[J]. Cancer Res, 2014, 74(11): 2913-2921. doi: 10.1158/0008-5472.CAN-14-0155
    [4]
    Chong HK, Wang T, Lu HM, et al. The validation and clinical implementation of BRCAplus: a comprehensive high-risk breast cancer diagnostic assay[J]. PLoS One, 2014, 9(5): e97408. doi: 10.1371/journal.pone.0097408
    [5]
    毛铁波, 崔玖洁, 王理伟.胰腺癌综合治疗的进展与突破[J].循证医学, 2019, 19(5): 257-260. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xzyx201905001

    Mao TB, Cui JJ, Wang LW. Progress and Breakthrough in The Comprehensive Treatment of Pancreatic Cancer[J]. Xun Zheng Yi Xue, 2019, 19(5): 257-260.] http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xzyx201905001
    [6]
    Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINO X in patients with borderline resectable pancreatic cancer:A systematic review and patient-level meta-analysis[J]. J Natl Cancer Inst, 2019, 111(8): 782-794. doi: 10.1093/jnci/djz073
    [7]
    Ciabatti S, Cammelli S, Frakulli R, et al. Radiotherapy of pancreatic cancer in older patients: A systematic review[J]. J Geriatr Oncol, 2019, 10(4): 534-539. doi: 10.1016/j.jgo.2018.09.007
    [8]
    Sakurai H, Ishikawa H, Okumura T. Proton beam therapy in Japan: current and future status[J]. Jpn J Clin Oncol, 2016, 46(10): 885-892. doi: 10.1093/jjco/hyw102
    [9]
    Hong TS, Wo JY, Borger DR, et al. Phase Ⅱ Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype[J]. J Natl Cancer Inst, 2017, 109(9). https://pubmed.ncbi.nlm.nih.gov/28954285/
    [10]
    王小琴, 陈耀龙, 渠清源, 等.病例系列研究方法学质量评价工具解读[J].中国循证儿科杂志, 2015, 10(5): 381-385. doi: 10.3969/j.issn.1673-5501.2015.05.012

    Wang XQ, Chen YL, Qu QY, et al. Interpretation of methodological quality assessment tools for case series studies[J]. Zhongguo Xun Zheng Er Ke Za Zhi, 2015, 10(5): 381-385.] doi: 10.3969/j.issn.1673-5501.2015.05.012
    [11]
    Terashima K, Demizu Y, Hashimoto N, et al. A phaseⅠ/Ⅱ study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis[J]. Radiother Oncol, 2012, 103(1): 25-31. https://pubmed.ncbi.nlm.nih.gov/22300608/
    [12]
    Shinoto M, Yamada S, Terashima K, et al. Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer[J]. Int J Radiat Oncol Biol Phys, 2016, 95(1): 498-504. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=f015ae31b5fe103046d093741a32333c
    [13]
    Maemura K, Mataki Y, Kurahara H, et al. Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer[J]. Pancreatology, 2017, 17(5): 833-838. doi: 10.1016/j.pan.2017.07.191
    [14]
    Hiroshima Y, Fukumitsu N, Saito T, et al. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer[J]. Radiother Oncol, 2019, 136: 37-43. doi: 10.1016/j.radonc.2019.03.012
    [15]
    Shinoto M, Shioyama Y, Matsunobu A, et al. Dosimetric analysis of upper gastrointestinal ulcer after carbon-ion radiotherapy for pancreatic cancer[J]. Radiother Oncol, 2016, 120(1): 140-144. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=b773f9899123be5d5860c7dbe2914625
    [16]
    Kawashiro S, Yamada S, Okamoto M, et al. Multi-institutional Study of Carbon-ion Radiotherapy for Locally Advanced Pancreatic Cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1403 Pancreas[J]. Int J Radiat Oncol Biol Phys, 2018, 101(5): 1212-1221. doi: 10.1016/j.ijrobp.2018.04.057
    [17]
    Shinoto M, Terashima K, Suefuji H, et al. A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer[J]. Radiother Oncol, 2018, 129(2): 333-339. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=a2eaf8e052763b1f808a5ac867dcbb95
    [18]
    Takatori K, Terashima K, Yoshida R, et al. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer[J]. J Gastroenterol, 2014, 49(6): 1074-1080. doi: 10.1007/s00535-013-0857-3
    [19]
    Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer[J]. N Engl J Med, 2018, 379(25): 2395-2406. doi: 10.1056/NEJMoa1809775
    [20]
    Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by Capecitabine-based chemoradiation for borderline resectable pancreatic cancer:Alliance for clinical trials in oncology trial A021101[J]. JAMA Surg, 2016, 151(8): e161137. doi: 10.1001/jamasurg.2016.1137
    [21]
    Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: A systematic review and patient-level meta-analysis[J]. J Natl Cancer Inst, 2019, 111(8): 782-794. doi: 10.1093/jnci/djz073
    [22]
    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 364(19): 1817-1825. doi: 10.1056/NEJMoa1011923
    [23]
    Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-Paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase Ⅰ/Ⅱ trial[J]. J Clin Oncol, 2011, 29(34): 4548-4554. doi: 10.1200/JCO.2011.36.5742
    [24]
    Chiorean EG, Cheung WY, Giordano G, et al. Real-world comparative effectiveness of nab-Paclitaxel plus Gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: A systematic review[J]. Ther Adv Med Oncol, 2019, 11: 1758835919850367. https://www.researchgate.net/publication/333217022_Real-world_comparative_effectiveness_of_nab-paclitaxel_plus_gemcitabine_versus_FOLFIRINOX_in_advanced_pancreatic_cancer_a_systematic_review
    [25]
    Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer[J]. N Engl J Med, 2019, 381(4): 317-327. doi: 10.1056/NEJMoa1903387
    [26]
    Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection[J]. Arch Surg, 1985, 120(8): 899-903. doi: 10.1001/archsurg.1985.01390320023003
    [27]
    Fogel EL, Shahda S, Sandrasegaran K, et al. A multidisciplinary Approach to Pancereas Cancer in 2016: A Review[J]. Am J Gastroenterol, 2017, 112(4): 537-554. doi: 10.1038/ajg.2016.610
    [28]
    Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891[J]. Ann Surg, 2007, 246(5): 734-740. doi: 10.1097/SLA.0b013e318156eef3
    [29]
    Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer[J]. J Clin Oncol, 2009, 27(11): 1806-1813. doi: 10.1200/JCO.2008.17.7188
    [30]
    Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy vs. Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial[J]. JAMA, 2016, 315(17): 1844-1853. doi: 10.1001/jama.2016.4324
    [31]
    Ng SP, Herman JM. Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer[J]. Cancers (Basel), 2018, 10(3):75. doi: 10.3390/cancers10030075
    [32]
    Uhl M, Mattke M, Welzel T, et al. High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results[J]. Cancer, 2014, 120(10): 1579-1585. doi: 10.1002/cncr.28606
    [33]
    Sahgal A, Chan MW, Atenafu EG, et al. Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes[J]. Neuro Oncol, 2015, 17(6): 889-894. doi: 10.1093/neuonc/nou347
    [34]
    Grutters JP, Kessels AG, Pijls-Johannesma M, et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis[J]. Radiother Oncol, 2010, 95(1): 32-40.
    [35]
    王小虎, 田金徽, 张秋宁, 等.碳离子治疗前列腺癌的Meta分析[J].中华放射医学与防护杂志, 2016, 36(8): 588-593. doi: 10.3760/cma.j.issn.0254-5098.2016.08.007

    Wang XH, Tian JH, Zhang QN, et al. A Meta-analysis of carbon ion radiotherapy for prostate cancer[J]. Zhonghua Fang She Yi Xue Yu Fang Hu Za Zhi, 2016, 36(8): 588-593. doi: 10.3760/cma.j.issn.0254-5098.2016.08.007
    [36]
    Jolnerovski M, Salleron J, Beckendorf V, et al. Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six-year outcomes and predictors of late toxicity[J]. Radiat Oncol, 2017, 12(1): 99.
    [37]
    Mizoe JE, Hasegawa A, Jingu K, et al. Results of carbon ion radiotherapy for head and neck cancer[J]. Radiother Oncol, 2012, 103(1): 32-37. https://pubmed.ncbi.nlm.nih.gov/22321201/
    [38]
    Shinoto M, Yamada S, Yasuda S, et al. Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer[J]. Cancer, 2013, 119(1): 45-51. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=9829a4c377ac2d276eb3fda5389b5bc4
    [39]
    Thompson RF, Mayekar SU, Zhai H, et al. A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas[J]. Med Phys, 2014, 41(8): 081711. https://pubmed.ncbi.nlm.nih.gov/25086521/

Catalog

    Article views (1968) PDF downloads (418) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return